Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2020

Filing Date
Filed February 25, 2021
Period End
December 31, 2020
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K filed February 25, 2021. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported total sales of $47.994 billiona for the fiscal year ending December 30, 2020, representing a 2% increase over the previous year, or 4% excluding foreign exchange impacts.

This growth was primarily driven by strong performance in the oncology franchise, particularly with Keytruda, and increased sales in certain hospital acute care products and the animal health division. Despite facing headwinds from the COVID-19 pandemic, which negatively impacted sales of physician-administered products by an estimated $2.5 billionb, Merck demonstrated resilience. The company advanced its strategic priorities, including completing significant business development transactions and investing in its pipeline.

A key strategic move was the announcement of the planned spin-off of its Women's Health, Biosimilars, and Established Brands businesses into a new entity, Organon & Co., expected in the latter half of 2021. This spin-off aims to create two focused companies, allowing each to better pursue its respective market opportunities and strategies.

Key Highlights

  1. Total sales reached $47.994 billion, a 2% increase year-over-year (4% excluding foreign exchange).
  2. The oncology franchise, led by Keytruda, was a primary growth driver, with Keytruda sales increasing by 30% to $14.38 billion.
  3. Merck announced plans to spin off its Women's Health, Biosimilars, and Established Brands businesses into a new company, Organon & Co., expected in the second quarter of 2021.
  4. The company made strategic acquisitions and collaborations in 2020 to bolster its pipeline, including ArQule, VelosBio, and partnerships for oncology and COVID-19 treatments.
  5. The COVID-19 pandemic had an estimated $2.5 billion negative impact on sales, primarily affecting physician-administered products and vaccines.
  6. Despite pandemic-related challenges, research and development expenses increased by 37% to $13.6 billion, reflecting investments in business development and pipeline advancement.
  7. Merck announced an increase in its quarterly dividend to $0.65 per share.

Follow one dollar

Of each $1.00 of revenue in FY2020, Merck kept $0.17.

  1. Revenue$41.52B100.0%
  2. Cost of revenue−$13.62B32.8%
  3. Gross profit$27.90B67.2%
  4. Operating costs−$23.38B56.3%
  5. Operating income$4.52B10.9%
  6. Interest, other & tax$2.55B6.1%
  7. Net income$7.07B17.0%
Computed from 10-KFY2020filed February 25, 2021Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2020 revenue went

$41.52B
  • Cost of revenue: $13.62B, 33% of revenue
  • R&D: $13.40B, 32% of revenue
  • SG&A: $8.96B, 22% of revenue
  • Operating income: $4.52B, 11% of revenue
  • Other operating costs: $1.03B, 2.5% of revenue

Kept 11% as operating income

Full revenue history →

Financial Statements

FY2020 against FY2019

Line itemFY2020FY2019Change
Revenue$41.52B$39.12B+6.1%
Cost of Revenue$13.62B$12.02B+13.3%
Gross Profit$27.90B$27.11B+2.9%
R&D Expenses$13.40B$9.72B+37.8%
SG&A Expenses$8.96B$9.46B−5.3%
Operating Income$4.52B$5.69B−20.6%
Interest Expense$831.00M$893.00M−6.9%
Net Income$7.07B$9.84B−28.2%
EPS (Basic)$2.79$3.84−27.3%
EPS (Diluted)$2.78$3.81−27.0%
Shares Outstanding (Basic)2.53B2.56B−1.4%
Shares Outstanding (Diluted)2.54B2.58B−1.5%

Frequently Asked Questions

  1. What was Merck's overall financial performance in 2020?

    Merck reported total sales of $47.994 billion in 2020, a 2% increase from 2019, or 4% excluding foreign exchange impacts. This growth was mainly driven by oncology products like Keytruda, as well as improvements in certain hospital acute care products and the animal health segment. However, the COVID-19 pandemic negatively impacted sales, with an estimated $2.5 billion reduction, primarily in the Pharmaceutical segment.

  2. What are the key growth drivers for Merck?

    Merck's key growth drivers include its oncology franchise, particularly the anti-PD-1 therapy Keytruda, which saw a 30% increase in sales to $14.38 billion. Other significant contributors to growth were certain vaccines, such as Gardasil/Gardasil 9 and Pneumovax 23, and hospital acute care products like Bridion and Prevymis. The Animal Health segment also showed positive sales growth.

  3. What is the significance of the planned Organon spin-off?

    Merck announced its intention to spin off its Women's Health, Biosimilars, and Established Brands businesses into a new, independent company named Organon & Co. This strategic move is expected to be completed in the latter half of 2021 and aims to create two focused companies, allowing each to concentrate on its specific strengths and market opportunities, thereby enhancing strategic flexibility and value creation.

  4. How did the COVID-19 pandemic affect Merck's business?

    The COVID-19 pandemic had a notable negative impact on Merck's 2020 performance, primarily affecting its Pharmaceutical segment. Sales were reduced by an estimated $2.5 billion due to factors such as reduced patient access to healthcare providers, fewer well visits, and delays in elective surgeries, which particularly impacted physician-administered products and vaccines. However, Merck stated that global health systems and patients have largely adapted, and ongoing residual negative impacts were expected to persist into 2021, particularly impacting vaccine sales.